Full Text
PAR4 COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB AS A NEW THERAPEUTIC OPTION FOR RHEUMATOID ARTHRITIS IN THE UK

Abstract

Authors

D Porter G Lewis B Brown A Diamantopoulos A Kielhorn

Back to Volume 9, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×